LUMENHANCE
LOE ApproachingNDAORALFOR SOLUTION
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMENHANCE is an oral solution approved by the FDA in December 1997 as a standard NDA product from Bracco. The mechanism of action and specific indications are not publicly disclosed in available data. Patient population and therapeutic use require additional clinical documentation.
LOE Approaching
As a mature product with LOE approaching, commercial teams are likely smaller and focused on market defense rather than expansion or growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LUMENHANCE offers limited career growth given zero linked job openings and approaching LOE status. Roles available are primarily defensive commercial positions or regulatory compliance functions for a legacy product transitioning to generic market.
Field Sales RepresentativeBrand Manager
Worked on LUMENHANCE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.